Huntington's Disease Market Forecast to 2024 in 7 Major Countries

PUNE, India, January 21, 2016 /PRNewswire/ --

New market research titled "EpiCast Report: Huntington's Disease - Epidemiology Forecast to 2024" provides an overview of the risk factors, comorbidities and global trends for Huntington's disease (HD) in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of HD and juvenile HD, diagnosed prevalent cases of Huntington's disease by age at onset, and diagnosed prevalent cases of adults with juvenile onset HD that progressed to adulthood, segmented by age and sex.

Complete report on Huntington's Disease - Epidemiology with 12 market data tables and 9 figures, spread across 49 pages is available at http://www.reportsnreports.com/reports/457215-epicast-report-huntingtons-disease-epidemiology-forecast-to-2024.html .

Huntington's disease (HD) is a rare, inherited, genetic disorder that causes progressive degeneration of the nerve cells of the brain especially the caudate, the putamen, and the cerebral cortex. As the brain cells die, a person with HD is unable to control movements, recall events, make decisions, and control emotions, and the disorder leads to incapacitation, cognitive and psychiatric disorders, and eventually death. The signs and symptoms of HD mostly appear between the ages 30-40 years, although the onset of disease may occur earlier or later in life. Therefore the disease is mostly of adult onset. The average lifespan of a person after being diagnosed with adult-onset HD is about 15-20 years. When the onset of the disease begins earlier than the age 20 years, the condition is called juvenile HD. Juvenile HD presents somewhat different symptoms and has a faster disease progression.

Epidemiologists forecast an increase in the diagnosed prevalence of HD over the ten-year forecast period. The number of diagnosed prevalent cases of HD in the 7MM will increase from 57,314 cases in 2014 to 60,743 cases in 2024, with an AGR of 0.60% during the forecast period. For juvenile HD, GlobalData epidemiologists forecast an increase from 1,000 diagnosed prevalent cases in 2014 to 1,013 diagnosed prevalent cases in 2024, in the 7MM, with an AGR of 0.13%.

Order a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=457215 .

Epidemiologists used the available data on HD to the best extent possible to provide the most insightful epidemiological forecast for the diagnosed prevalent cases of HD, diagnosed prevalent cases of juvenile HD, diagnosed prevalent cases of HD by age at onset, and diagnosed prevalent cases of adults with juvenile-onset HD that progressed to adulthood in the 7MM. All sources for the 7MM assessed HD by diagnostic testing, including genetic tests. Additionally, the forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the projected diagnosed prevalent cases of HD across the markets.

Another newly published market research titled Tauopathies - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Tauopathies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tauopathies and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Tauopathies Pipeline Review Research Report with 54 pages is available at http://www.reportsnreports.com/reports/453510-tauopathies-pipeline-review-h2-2015.html .

More reports on pharmaceuticals market are available at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:  http: //http://www.reportsnreports.com/feed/l-latestreports.xml